TW202128030A - A use of manufacturing a composition for improving the immunity - Google Patents

Abstract

The present invention provides a use of manufacturing a composition for improving the immunity, wherein the composition comprises the mycelium ofLactobacillus or the active substance thereof and theLactobacillus is selected from the group consisting ofBifidobacterium lactis ,Lactobacillus rhamnosus ,Lactobacillus plantarum , andLactobacillus fermentum or the combination thereof.

Description

Use for preparing composition for enhancing immunity

This disclosure relates to a use of a composition for improving immunity; more specifically, the composition contains an active substance of a lactic acid bacteria, wherein the lactic acid bacteria is selected from Bifidobacterium lactis (Bifidobacterium lactis), rhamnose milk One or a combination of Lactobacillus rhamnosus , Lactobacillus plantarum , or Lactobacillus fermentum. By administering the composition to the mother, the immunity of the offspring is enhanced.

Immune response and antibodies

When a specific foreign pathogen (antigen) invades the human body, the human body has a series of defense mechanisms to resist the foreign substance, that is, the immune response. B cells, which are immune cells in the human body, will produce antibodies after being stimulated by antigens. The so-called antibody is a glycoprotein, also known as immunoglobulin (Ig). Antibodies can bind to antigens and achieve the effect of defense against further invasion of the human body by foreign objects in the immune response. Generally, mammalian immunoglobulins are divided into five types, namely IgM, IgG, IgA, IgE and IgD.

Immunoglobulin in adult individuals

Immunoglobulin IgM is a low-affinity antibody, mainly involved in the primary immune response. In other words, IgM, like the vanguard, is the first antibody produced after stimulation, effectively resisting foreign pathogens in the early immune response. Next, IgG, the main circulating immunoglobulin in the human body, is a high-affinity antibody. IgG will be produced in large quantities and can be maintained for a long time, and can help the human body to shorten the time of immune response when encountering the second invasion of the same pathogen. This means that IgG provides long-term immune protection. In addition, the secreted immunoglobulin IgA mainly acts on the human mucosal immune system, such as the digestive tract, respiratory tract, and genitourinary system. When foreign pathogens invade the human body and stimulate the local immune system, IgA will participate in the immune response of the mucosal system for a short time. Immunoglobulin IgE is a kind of cell-philic antibody, which is related to the immunity of the respiratory tract, parasites, and skin allergies. The content of immunoglobulin IgD in the human body is relatively small, and current studies have pointed out that this antibody is related to autoantibodies and antiviral antibodies.

Immune globulin in fetus, early childhood, etc.

Because of the amniotic membrane barrier in the mother's body, the offspring will not be affected by foreign pathogens, and there will be no subsequent immune response. However, the offspring begins to be exposed to pathogens from the outside world after they are born. At this time, the daughter itself will not synthesize immunoglobulin by itself to resist foreign pathogens. Therefore, the key to the immunity of offspring in infants, neonates, and early childhood lies in the mother. Specifically, most of the daughters obtain antibodies through the mother. Generally speaking, progeny can synthesize antibody IgG by themselves within 3 months after birth. The IgG concentration in the progeny is not close to that of an adult until the pre-childhood of about 3 to 5 years old. Immunoglobulin IgG is the only antibody that can pass through the placenta and provide immunity to the offspring during the fetal period. In addition to IgG, another related to the immunity of the daughter is the immunoglobulin IgA. Antibody IgA is generally self-synthesized 4 to 6 months after birth. The IgA concentration of the offspring can reach 25% of the adult idiosyncratic IgA concentration after about one year of age in early childhood. Although IgA cannot pass through the placenta, it is abundantly present in the mother's breast milk. Therefore, the child can obtain IgA from the mother during the process of penetrating the mother and the child. In this way, the immune system of the offspring can be improved, and the infection of the respiratory tract and intestinal tract can be effectively avoided. As mentioned above, the immune mechanism of the offspring in the fetus, newborn, infant and early childhood is different from that of the adult individual. The immunity of the offspring is mostly obtained from the mother by means of supplementation.

Probiotics and immunity

It is known that probiotics have a variety of effects on the human body, such as improving the gastrointestinal tract, regulating allergies, protecting the liver, and enhancing muscle strength. Many literatures also point out that probiotics can be used to enhance immunity. Studies have found that probiotics can promote the toxicity of natural killer cells and the phagocytic ability of macrophages, and enhance non-specific immune responses. In addition, probiotics can also regulate the performance of intestinal Th1, Th2, Treg and other cells to achieve anti-inflammatory or pro-inflammatory effects.

Since the immunity of the offspring depends on the immunoglobulin provided by the mother, there is still a need to develop lactic acid bacteria strains supplemented by the mother during pregnancy and lactation in order to enhance the immunity of the offspring.

The present disclosure provides a use for preparing a composition for enhancing immunity, wherein the composition comprises a lactic acid bacteria cell or an active substance thereof, wherein the lactic acid bacteria is selected from Bifidobacterium lactis and Lactobacillus rhamnosus One or a combination of Lactobacillus rhamnosus , Lactobacillus plantarum , and Lactobacillus fermentum.

Preferably, the Bifidobacterium lactis GKK2 is deposited with BCRC 910826, Lactobacillus rhamnosus GKLC1 with BCRC 910828, Lactobacillus embryonicum GKM3 with BCRC 910787 or Lactobacillus fermentum GKF3 with BCRC 910824, and is deposited in the Food Industry Development Research Consortium Institute of Biological Resources Research Center.

Preferably, wherein the composition is administered in an effective amount as a subject-mother.

Preferably, the composition is administered during pregnancy or lactation of the mother.

Preferably, the immunity refers to the immunity of a daughter of the mother.

Preferably, the immunity refers to the immunity of the offspring in the fetus, newborn, infant, or infant stage.

Preferably, the immunity refers to the concentration of immunoglobulin in the serum of the progeny.

Preferably, the improvement of immunity refers to the higher concentration of immunoglobulin in the serum of the offspring of the parent administered the composition compared to the offspring of the parent administered the composition.

Preferably, wherein the immunoglobulin (Ig) is IgG or IgA.

Preferably, the active substances of the lactic acid bacteria are prepared by the following method:

(A) Inoculating the bacteria of the lactic acid bacteria in a solid medium for solid culture to form colonies;

(B) Inoculating the colony cultured in step (a) in a liquid medium for liquid culture to obtain a liquid medium containing bacteria;

(C) Inoculating the liquid medium containing bacteria in step (b) in the fermentation tank for liquid amplification to obtain the bacteria liquid;

(D) Centrifuge the bacterial liquid of step (c) to obtain bacterial sludge;

(E) freeze-drying the bacterial paste in step (d) as bacterial powder; and

(F) Extract the bacterial powder of step (e) with an alcohol as a solvent to obtain an alcohol extract.

Preferably, the freeze-drying temperature is -196 to -40°C.

Preferably, the alcohol is methanol, ethanol, isopropanol or a combination thereof.

Preferably, the amount of the alcohol added is about 9 to 11 times the volume of the bacterial powder.

Preferably, the extraction is ultrasonic vibration extraction for about 0.5 to 1.5 hours.

Preferably, the composition includes an additive selected from the following group: excipients, preservatives, diluents, fillers, absorption enhancers, sweeteners, or combinations thereof.

Preferably, the composition is a medicine, feed, beverage, nutritional supplement, dairy product, food or health food.

Preferably, the form of the composition is powder, lozenge, suppository, microcapsule, ampoule, liquid spray or suppository.

As used herein, "immunity" refers to a protective response by an organism to recognize and eliminate antigenic substances. In a specific aspect, immunity refers to the concentration of immunoglobulin in the organism's serum.

The "bacteria" mentioned herein refers to the structure of the lactic acid bacteria themselves in various cultivation stages of the lactic acid bacteria used in this disclosure. In a specific aspect, the bacterial system refers to a complete or partial structure of lactic acid bacteria. In a specific aspect, the bacterial system refers to the colony of the lactic acid bacteria group formed by the division and reproduction of a single bacteria. In a specific aspect, the culture stage refers to liquid culture or liquid amplification inoculated in a fermentation tank.

The "active substance" mentioned herein refers to the substance selected from the lactic acid bacteria cells used in the present disclosure after being processed by specific experimental steps, or the mixture of the bacteria cells and the culture medium or culture solution. In a specific aspect, the active substance refers to the centrifugally separated bacterial mud, freeze-dried bacterial powder or solvent-extracted extract. In a specific aspect, the active substance refers to a solid medium containing bacterial cells, a liquid medium containing bacterial cells, or a bacterial liquid amplified in a liquid state in a fermentation tank.

As used herein, the "effective amount" refers to an amount used, which is sufficient to produce the aforementioned immunity-boosting effect.

The "pregnancy" referred to in this article is also called pregnancy, which refers to the process of embryo or fetus growth in the body of a mammalian female.

In this article, "breastfeeding" is also referred to as breastfeeding, lactation, lactation or breastfeeding. Lactation refers to the behavior of a female mother feeding her offspring with her breast.

The term "fetus" as used herein refers to a human individual from the eighth week after the formation of the fertilized egg until delivery.

As used herein, "newborn" refers to a human individual between 0 and 5 weeks of age.

As used herein, "infant" refers to a human individual between 5 weeks and 1 year old.

As used herein, "children" refer to human individuals between the ages of 1-3.

The child’s immunity is not as good as the human adult during the fetal period before the mother’s childbirth, as well as the newborn, infant, and toddler years after the mother’s childbirth. This is because immunoglobulins begin to be autologously synthesized after a certain period of time after birth, so the offspring need to obtain immunoglobulins from the mother.

In order to enhance the immunity of the progeny, the present disclosure has developed a composition containing a lactic acid bacteria cell and its active substance. The composition is administered to the mother, and the immunoglobulin is administered to the child through the mother's placenta or breastfeeding to achieve the effect of increasing the concentration of the child's immunoglobulin. In a preferred embodiment, the lactic acid bacteria contained in the composition are selected from Bifidobacterium lactis , Lactobacillus rhamnosus , Lactobacillus plantarum or fermented milk. One or a combination of the group consisting of Lactobacillus fermentum. In a preferred embodiment, the above-mentioned lactic acid bacteria are sequentially deposited with GKK2 (BCRC 910826), GKLC1 (BCRC 910828, GKM3 (BCRC 910787) or GKF3 (BCRC 910824).

Regarding the culture of bacteria, lactic acid bacteria are inoculated on a solid medium to perform solid culture to activate the bacteria and form colony formation. In a preferred embodiment, the temperature of the solid-state culture is 30 to 55°C, more preferably 32 to 45°C. In a preferred embodiment, the solid-state culture time is 0.5 to 3 days, more preferably 1 to 2.5 days. In a preferred embodiment, the solid medium is MRS agar. After the growth of the colony on the solid medium is completed, a single colony is picked up and inoculated into a test tube containing MRS liquid medium, and activated by liquid culture. In a preferred embodiment, the temperature of MRS liquid culture is 30 to 55°C, more preferably 32 to 45°C. In a preferred embodiment, the time for the liquid culture of MRS is 14 to 18 hours, more preferably 16 hours. The bacteria in the MRS liquid culture medium were inoculated into a conical flask containing 1 L of liquid culture medium. In a preferred embodiment, the pH value of the liquid culture is pH 5.0 to 7.0, more preferably pH 5.5 to 6.5. In a preferred embodiment, the formula of the liquid culture medium is as shown in Table 1 below. After the growth of the bacteria in the liquid culture medium is completed, the bacteria and the liquid culture medium are inoculated into the fermentation tank for liquid amplification to obtain a bacteria-containing liquid. In a preferred embodiment, the culture temperature in the fermentation tank is 30 to 55°C, more preferably 32 to 45°C. In a preferred embodiment, the culture time in the fermentation tank is 16 to 20 hours, more preferably 17 to 19 hours.

Table 1 Element Proportion (weight percentage) Carbon source 0 to 10% Soy milk 0.1~5% Nitrogen source 0.1~5% ion 0.01~2% water The remaining part

Regarding the preparation of the bacterial powder, after the bacterial cells are grown in the liquid culture, the bacterial liquid of the liquid medium containing the bacterial cells is collected. Next, the bacterial liquid is centrifuged to remove the liquid medium used for fermentation to obtain bacterial sludge. In a preferred embodiment, the centrifugation rate of the liquid culture medium containing the bacteria is 1000 to 15000 rpm. The obtained bacterial mud is mixed with the protective agent and then freeze-dried to obtain bacterial powder, and the freeze-dried bacterial powder is stored at low temperature. In a preferred embodiment, the protective agent is 6 to 30% skimmed milk powder. In a preferred embodiment, the storage temperature is 0°C to 8°C, more preferably 2°C to 6°C. The preserved bacterial powder is used as the test substance in the following animal experiments.

The present disclosure discloses a composition containing lactic acid bacteria cells and active substances thereof, and further contains additives. In a preferred embodiment, the additives can be excipients, preservatives, diluents, fillers, absorption enhancers, sweeteners, or combinations thereof. The excipient can be selected from sodium citrate, calcium carbonate, calcium phosphate, sucrose or a combination thereof. The preservative can extend the shelf life of the pharmaceutical composition, such as benzyl alcohol and parabens. The diluent may be selected from water, ethanol, propylene glycol, glycerin, or a combination thereof. The filler may be selected from lactose, nougat, high molecular weight ethylene glycol, or a combination thereof. The absorption enhancer may be selected from dimethyl sulfide (DMSO), azodipine, propylene glycol, glycerin, polyethylene glycol, or a combination thereof. The sweetener may be selected from Acesulfame K, aspartame, saccharin, sucralose, neotame, or a combination thereof. In addition to the additives listed above, other suitable additives can be selected according to requirements without affecting the medicinal effect of the composition.

The composition can be developed into different commodities in the field of medicine. In a preferred embodiment, the composition is a medicine, feed, beverage, nutritional supplement, dairy product, food or health food.

Under the premise that the composition of the present disclosure does not affect the effect of the bacteria or the active substance, the composition can be made into any pharmaceutical form according to the needs of the recipient. In a preferred embodiment, the composition is in the form of powder, lozenge, suppository, microcapsule, ampoule/ampule, liquid spray or suppository.

According to the composition of the present disclosure, a suitable dosage of the composition is administered to the subject by a suitable route at a predetermined time point according to the type of the composition. In a preferred embodiment, the route of administration includes oral or parenteral, and also includes intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal, respiratory (aerosol), rectal, vaginal or topical (including Oral cavity and sublingual). In a preferred embodiment, the predetermined time point includes every meal, every day, and every week. In a preferred embodiment, the subject is a human or animal. In a preferred embodiment, the mother as the subject provides immunoglobulin to the offspring through the placenta or breastfeeding, so the subject is a mother during pregnancy or breastfeeding.

The effective amount is used in in vitro cell culture experiments. The total volume of cell culture medium used in each culture is defined as "μg/ml". In animal experiments, the effective amount is defined as "g/60 kg body weight/day". According to the following calculation formula, the effective amount obtained from the in vitro cell culture experiment can be converted into an effective amount for animals, and the effective amount for animals can be converted into an effective amount for humans according to the metabolic rate. I. Generally (Reagan-Shaw et al ., 2008), 1 "μg/ml" unit (based on the effective amount obtained from in vitro cell culture experiments) can be equivalent to 1 "mg/kg body weight/day" unit ( Based on the effective amount obtained from the rat model experiment). Based on the known that the metabolic rate of rats is 6.2 times that of humans, the effective dose of humans can be further obtained. II. If the effective amount is 500 μg/ml based on in vitro cell culture experiments, the effective amount used in rats can be calculated as 500 mg/kg body weight/day (ie, 0.5 g/kg body weight/day ). Further, taking into account the aforementioned difference in metabolic rate, the effective amount for human use can be calculated as about 5 g/60 kg body weight/day. III. According to the following test results, the effective dose based on the rat test is 2000 mg/kg body weight/day, and the effective dose for humans calculated by the above conversion formula is about 20 g/60 kg body weight/day.

In a preferred embodiment, the effective amount of lactic acid bacteria cells or active substances contained in the composition is 2 g to 40 g/60 kg body weight/day, more preferably 5 g to 30 g/60 kg body weight/day, more preferably 10 g to 25 g/60 kg body weight/day.

Example 1: Source of strains

The bacteria used to prepare the test substance in the examples of this disclosure were purchased from the Bioresource Conservation and Research Center of the Food Industry Development Institute. The names and deposit numbers of these strains are shown in Table 2. However, the strains described in the present disclosure are not limited to obtaining through channels, and those with ordinary knowledge in the technical field can also obtain strains of these lactic acid bacteria from other microorganism strain preservation units.

Table 2: Strains serial number name Deposit number 1 Bifidobacterium lactis GKK2 (Bifidobacterium lactis) BCRC 910826 2 Lactobacillus rhamnosus GKLC1 (Lactobacillus rhamnosus) BCRC 910828 3 Lactobacillus plantarum GKM3 (Lactobacillus plantarum) BCRC 910787 4 Lactobacillus fermentum GKF3 (Lactobacillus fermentum) BCRC 910824

Example 2: Bacteria culture

The lactic acid bacteria cells were inoculated on MRS agar as a solid medium, and solid-state culture was performed at 37°C for 2 days to activate the bacteria cells and form colony formation. After the growth of the colony on MRS agar is complete, pick up a single colony and inoculate it in a test tube containing MRS liquid medium. After incubating at 37°C for 16 hours, it is then inoculated into a 1L liquid medium with a pH value of 6.0 in an Erlenmeyer flask. The formulation of the medium is shown in Table 1 above. After the growth of the bacteria in the liquid medium is completed, the bacteria and the liquid medium are inoculated into a fermentation tank and cultured at 37° C. for 18 hours for liquid amplification to obtain a bacterial solution.

Example 3: Preparation of bacterial powder

After the bacterial cells are grown in the liquid culture, the bacterial liquid of the liquid medium containing the bacterial cells is collected. The bacterial liquid was centrifuged at 6000 rpm to remove the liquid medium and obtain bacterial sludge. After mixing the bacterial sludge with 15% skimmed milk powder as a protective agent, freeze-drying to obtain bacterial powder, and store the bacterial powder at 4°C. The preserved bacterial powder is used as the test substance in the following animal experiments.

Example 5: Detection of immunoglobulin concentration

Test animal

A total of 30 pregnant female mice of S prague-Dawley (SD) strain were purchased from BioLASCO Taiwan Co., Ltd., Taiwan. The animals are kept in the rat breeding room of the Taiwan-American Experimental Animal Center, and each female rat is individually kept in a cage. The room temperature is maintained at 22 ± 2°C, the humidity is 40~60%, the ventilation frequency is 10-15 times per hour, the regular 12 hours of light and darkness, feed and sterile reverse osmosis water are allowed to be eaten freely by the female rats. The newly-introduced female mice began to experiment after 3 days of acclimatization.

Test design

Thirty pregnant female mice were divided into five groups: a control group and an experimental group of 4 lactic acid bacteria strains, each with 6 female mice. On the 13th to 21st day of pregnancy and the 1st to 13th day of lactation (that is, the 1st to 13th day after delivery), the mother rats of the 4 experimental groups were administered by oral tube once a day. The bacterial powder of GKK2, GKLC1, GKM3, and GKF3, and the mother mice of the control group were given reverse osmosis water as the test substance. The dose of the test substance is 2,000 mg/kg B.W. (Body Weight).

Six pups from each group were injected intraperitoneally with OVA/CFA mixture (0.5 μg/pup) as the antigen to induce immune response 3 days after birth. The pups were sacrificed and blood was collected on the 13th day after birth. The blood samples of the collected young mice were used to determine the concentration of immunoglobulin IgG and IgA in the serum of the blood samples using commercially available kits (Mouse IgG ELISA Quantitation Set and Mouse IgA ELISA Quantitation Set, Bethyl).

Data processing and statistical analysis

The experimental data is expressed in terms of mean and standard deviation (S.D.). The test data was analyzed by Duncan's test method of One-Way ANOVA in SPSS statistical software, and the p-value was less than 0.05 as the significant difference level.

test results

The results of detecting the IgG concentration in the serum of young mice are shown in Figure 2. In the control group administered with reverse osmosis water during pregnancy, the IgG concentration in the serum of the young mice was 224.4. In the experimental group administered with lactic acid bacteria during pregnancy, the IgG concentration in the young mice's serum was 3042.3 in the GKK2 group, 3287.7 in the GKLC1 group, 3309 in the GKM3 group, and 2857.7 in the GKF3 group. After comparing the IgG concentration in the serum of each group, after OVA (ovalbumin) induction, the pups of mother mice that ingested lactic acid bacteria had a significantly higher immunoglobulin IgG concentration after birth than the pups of mothers that did not eat lactic acid bacteria ( p>0.05). Among them, the GKM3 group had the highest IgG concentration. This result indicates that the maternal intake of lactic acid bacteria during pregnancy, such as GKK2, GKLC1, GKM3 or GKF3, can raise the IgG antibody of the unborn fetus through the placenta, increase the IgG concentration of the offspring after birth, and achieve the effect of enhancing immunity.

The results of detecting the IgA concentration in the serum of young mice are shown in Figure 3. In the control group that was given reverse osmosis water when the mothers were breast-feeding, the IgA concentration in the serum of the young mice was 1025.9. In the experimental group administered with lactic acid bacteria when the mothers were breast-feeding, the IgA concentration in the young mice's serum was 6106 in the GKK2 group, 6767 in the GKLC1 group, 6854.6 in the GKM3 group, and 3612.7 in the GKF3 group. After comparing the IgA concentration in the serum of each group, after OVA (ovalbumin) induction, the pups of mother mice that ingested lactic acid bacteria had a significantly higher immunoglobulin IgA concentration after birth than the pups of mothers that did not eat lactic acid bacteria ( p>0.05). Among them, the GKM3 group had the highest IgA concentration. This result shows that lactating mothers ingested lactic acid bacteria, such as GKK2, GKLC1, GKM3 or GKF3, can raise the antibody IgA of the born offspring through breastfeeding, and increase the IgA concentration of the offspring after birth to enhance immunity Effect.

Example 6: Composition preparation

If the strain of the present disclosure is applied to food use, the following compositions 1 to 2 are taken as illustrative examples.

Composition 1: Take Bifidobacterium lactis GKK2 (Bifidobacterium lactis) BCRC 910826 powder (20 wt%), and mix it thoroughly with benzyl alcohol (8 wt%) as preservative and glycerin (7 wt%) as diluent, It is dissolved in pure water (65 wt%) and stored at 4°C for later use. The aforementioned wt% refers to the proportion of each component to the total weight of the composition.

Composition 2: Replace the bacterial powder of Bifidobacterium lactis (Bifidobacterium lactis) BCRC 910826 of Composition 1 with the bacterial powder of Lactobacillus rhamnosus GKLC1 (Lactobacillus rhamnosus) BCRC 910828 (20 wt%), and the rest of the composition and combination Item 1 is the same.

If the strains of the present disclosure are applied to medicinal purposes in liquid form, the following compositions 3 to 4 are taken as illustrative examples.

Composition 3: Take Lactobacillus plantarum (Lactobacillus plantarum) BCRC 910787 powder (20 wt%), benzyl alcohol (8 wt%) as preservative, glycerin (7 wt%) as diluent, and diluent The sucrose (10 wt%) is mixed thoroughly, dissolved in pure water (55 wt%), and stored at 4°C for later use. The aforementioned wt% refers to the proportion of each component to the total weight of the composition.

Composition 4: Replace the bacterial powder of Lactobacillus plantarum (Lactobacillus plantarum) BCRC 910787 of composition 4 with the bacterial powder of Lactobacillus fermentum GKF3 (Lactobacillus fermentum) BCRC 910824 (20 wt%), and the rest of the composition is the same as composition 3. .

without

Figure 1 shows the flow of animal experiments. The "pregnancy", "lactation" and "birth" marked on the upper part of the horizontal axis in the figure refer to the state or period of the young rat or its mother, and "d" refers to the day of the state or period. The double arrow line parallel to the horizontal axis in the figure refers to the period during which the test substance is administered. The "OVA/CFA" and "sacrifice" marked at the lower end of the horizontal axis in the figure refer to the experimental steps taken on the young rat.

Figure 2 shows the IgG concentration of the young mice in the serum of the control group and the experimental group after they were sacrificed.

Figure 3 shows the concentration of IgA in the serum of the young mice in the control group and the experimental group after sacrifice.

Bifidobacterium lactis GKK2 (Bifidobacterium lactis) BCRC 910826

Lactobacillus rhamnosus GKLC1 (Lactobacillus rhamnosus) BCRC 910828

Lactobacillus plantarum GKM3 (Lactobacillus plantarum) BCRC 910787

Lactobacillus fermentum GKF3 (Lactobacillus fermentum) BCRC 910824

Claims (17)

A use for preparing a composition for enhancing immunity, wherein the composition comprises a lactic acid bacteria cell or an active substance thereof, wherein the lactic acid bacteria is selected from the group consisting of Bifidobacterium lactis and Lactobacillus rhamnosus ), one or a combination of Lactobacillus plantarum and Lactobacillus fermentum. The use according to claim 1, wherein the Bifidobacterium lactis GKK2 is deposited with BCRC 910826, Lactobacillus rhamnosus GKLC1 with BCRC 910828, Lactobacillus embryo GKM3 with BCRC 910787 or Lactobacillus fermentum GKF3 with BCRC 910824, deposited in the consortium The biological resources research center of the Food Industry Development Institute. The use according to claim 1, wherein the composition is administered as a parent of the subject in an effective amount. The use according to claim 3, wherein the composition is administered during pregnancy or lactation of the mother. The use according to claim 3, wherein the immunity refers to the immunity of a child of the mother. The use according to claim 5, wherein the immunity refers to the immunity of the offspring in the fetus, newborn, infant or early childhood. The use according to claim 5, wherein the immunity refers to the concentration of immunoglobulin in the serum of the progeny. The use according to claim 5, wherein the boosting of immunity refers to a higher concentration of immunoglobulin in the serum of the offspring of the parent administered the composition relative to the offspring of the parent administered the composition. The use according to claim 7, wherein the immunoglobulin (Ig) is IgG or IgA. The use described in claim 1, wherein the active substances of the lactic acid bacteria are prepared by the following method: (A) Inoculating the bacteria of the lactic acid bacteria in a solid medium for solid culture to form colonies; (B) Inoculating the colony cultured in step (a) in a liquid medium for liquid culture to obtain a liquid medium containing bacteria; (C) Inoculating the liquid medium containing bacteria in step (b) in the fermentation tank for liquid amplification to obtain the bacteria liquid; (D) Centrifuge the bacterial liquid of step (c) to obtain bacterial sludge; (E) freeze-drying the bacterial paste in step (d) as bacterial powder; and (F) Extract the bacterial powder of step (e) with an alcohol as a solvent to obtain an alcohol extract. The use according to claim 10, wherein the freeze-drying temperature is -196 to -40°C. The use according to claim 10, wherein the alcohol is methanol, ethanol, isopropanol or a combination thereof. The use according to claim 10, wherein the added amount of the alcohol is about 9 to 11 times the volume of the bacterial powder. The use according to claim 10, wherein the extraction is ultrasonic vibration extraction for about 0.5 to 1.5 hours. The use according to claim 1, wherein the composition comprises an additive selected from the following group: excipients, preservatives, diluents, fillers, absorption enhancers, sweeteners, or combinations thereof. The use according to claim 1, wherein the composition is a medicine, feed, beverage, nutritional supplement, dairy product, food or health food. The use according to claim 1, wherein the composition is in the form of powder, lozenge, suppository, microcapsule, ampoule, liquid spray or suppository.

Images